A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients – the ELDERS study

Older cancer patients are underrepresented in the pivotal trials of checkpoint inhibitors (CPIs). This study aimed to investigate the impact of an ageing immune system on CPI-related toxicity and provide evidence for the role of geriatric assessments with CPI. The ELDERS study is a prospective observational study with two cohorts: older (70+ years of age) and younger …
Continua a leggere

Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma

Patients with synchronous clinical stage III melanoma can present with primary melanoma lesions, locally recurrent melanoma or in-transit metastases. Neoadjuvant ipilimumab plus nivolumab induces high pathologic response rates and an impressive relapse-free survival in patients with nodal macroscopic stage III melanoma. Whether primary site melanoma and in-transit …
Continua a leggere

Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies

Historically, the prognosis for patients who have melanoma brain metastasis (MBM) has been dismal. However, breakthroughs in targeted and immunotherapies have improved long-term survival in those with advanced melanoma. Therefore, MBM presentation, prognosis, and the use of multimodality central nervous system (CNS)-directed treatment were reassessed. In this …
Continua a leggere

Digital Immunophenotyping Predicts Disease Free and Overall Survival in Early Stage Melanoma Patients

The prognostic significance of tumor infiltrating lymphocytes (TILs) in intermediate/thick primary cutaneous melanoma (PCM) remains controversial, partially because conventional evaluation is not reliable, due to inter-observer variability and diverse scoring methods. We aimed to assess the prognostic impact of the density and spatial distribution of immune cells in early …
Continua a leggere

Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas

Although the prognosis of patients with thin primary cutaneous melanomas (T1, ≤ 1.0 mm) is generally excellent, some develop recurrence. We sought to develop and validate a model predicting recurrences in patients with thin melanomas. A Dutch population-based cohort (n = 25,930, development set) and a cohort from an Australian melanoma treatment center …
Continua a leggere